Wenqin Ni

Wenqin Ni joined Pfizer in 2013 and currently serves as a Senior Principal Scientist. In this role, Wenqin leads multiple development programs from early-stage research—prior to clinical studies—through to commercial approval, including multispecific projects. Wenqin’s core expertise lies in CMC strategy, with a focus on critical quality attribute (CQA) assessment, control strategy development, and specification setting across diverse projects and modalities. Prior to joining Pfizer, Wenqin earned a Ph.D. from Northeastern University, where research was centered on the characterization of post-translational modifications in biologics using LC/MS.